Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical Trial
January 12, 2021 16:01 ET
|
Merus N.V.
UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus kündigt Präsentation der klinischen Daten der Phase I für MCLA-158 auf dem „2021 Gastrointestinal Cancers Symposium“ der American Society of Clinical Oncology (ASCO) an
January 12, 2021 12:47 ET
|
Merus N.V.
UTRECHT, Niederlande und CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Merus N.V.(Nasdaq: MRUS) („Merus“, „das Unternehmen“, „wir“ oder „unser“), ein Unternehmen aus dem Bereich der klinischen...
Merus annonce la présentation des données cliniques de phase 1 sur le MCLA-158 lors du Symposium sur les cancers gastro-intestinaux 2021 de l'American Society of Clinical Oncology (ASCO)
January 12, 2021 12:47 ET
|
Merus N.V.
UTRECHT, Pays-Bas, et CAMBRIDGE, Massachusetts, 12 janv. 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (« Merus », la « Société », « nous » ou « notre/nos »), une société d'oncologie de stade...
Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium
January 11, 2021 17:10 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing...
Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers
January 07, 2021 16:05 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus and Sema4 Enter Into an Agreement to Support Merus’ Phase 1/2 Clinical Trial of Zenocutuzumab
December 17, 2020 08:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and STAMFORD, Conn., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multi-specific...
Merus to Present at the Jefferies Virtual London Healthcare Conference
November 16, 2020 08:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer
November 09, 2020 08:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing...
Merus Announces Financial Results for the Third Quarter and Provides Business Update
November 05, 2020 16:10 ET
|
Merus N.V.
–Clinical data and program update planned for lead program Zenocutuzumab (“Zeno”) in 2Q 2021–– MCLA-129 expected to enter clinic in 2021 – UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 05,...
Merus und myTomorrows kündigen Ausbau ihrer Zusammenarbeit an, um Aufmerksamkeit für Screening und klinische eNRGy-Studie zur Behandlung von Krebspatienten mit Tumoren mit Neuregulin-1-Fusionen zu erhöhen
October 13, 2020 14:35 ET
|
Merus N.V.
UTRECHT, Niederlande, und CAMBRIDGE, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- myTomorrows, ein globales Unternehmen im Bereich Gesundheitstechnologien, und Merus N.V. (Nasdaq: MRUS), ein Unternehmen...